Anastasia V. Timakova
Anastasia V. Timakova has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Alena A. Kovaleva
Pirogov Russian National Research Medical University
1 shared publication - Elena V. Sibirskaya
N.I. Pirogov Russian National Research Medical University, Russian Children’s Clinical Hospital (Branch)
1 shared publication - Margarita S. Shirinyants
Peoples’ Friendship University of Russia
1 shared publication - Polina O. Nikiforova
N.I. Pirogov Russian National Research Medical University, Russian Children’s Clinical Hospital (Branch)
1 shared publication
Latest Publications
- 24 June 2026
- Published by ECO-Vector LLC (Publications) in Journal of obstetrics and women's diseases
- Vol. 75 (3) , 94-103
Efficiency and safety of ovarian plasma therapy in patients with poor ovarian response and premature ovarian insufficiency: a systematic review
Despite growing clinical interest in the administration of autologous platelet-rich plasma (PRP) in primary ovarian insufficiency and diminished ovarian reserve, data on its efficacy remain extremely limited and methodologically heterogeneous. There are no standardized protocols, and the effect of therapy on key clinical outcomes has not been sufficiently studied. It is necessary to systematize the available data in order to assess the current level of evidence and identify areas for further research. The aim of the study was to evaluate the effectiveness of PRP therapy in women with poor ovarian response and primary ovarian insufficiency. This systematic review included English-language publications evaluating the effectiveness of PRP therapy in women with diminished ovarian reserve and primary ovarian insufficiency for the period 1985–2025. The review is based on the PRISMA checklist. Randomized and non-randomized original clinical trials (prospective, retrospective, quasi-experimental, etc.) were used for the analysis. After searching for and excluding duplicates, 415 articles were screened, of which 4 studies were selected for qualitative synthesis. The included studies demonstrate that intraovarian PRP administration can help improve biomarkers of ovarian reserve (anti-Müllerian hormone, follicle-stimulating hormone, and antral follicle count), particularly in patients with poor ovarian response syndrome and after surgery. A positive trend in pregnancy and live birth rates was noted, with no increase in the rates observed. PRP therapy demonstrates potential effectiveness in improving ovarian reserve parameters. However, due to the small number of studies, their heterogeneity and varying risk of systematic error, the impact on final reproductive outcomes requires further research. Large, randomized, controlled trials are needed to standardize PRP preparation and administration protocols and define clear indications for therapy.
- 24 June 2026
- Published by ECO-Vector LLC (Publications) in Journal of obstetrics and women's diseases
- Vol. 75 (3) , 94-103
Efficiency and safety of ovarian plasma therapy in patients with poor ovarian response and premature ovarian insufficiency: a systematic review
Despite growing clinical interest in the administration of autologous platelet-rich plasma (PRP) in primary ovarian insufficiency and diminished ovarian reserve, data on its efficacy remain extremely limited and methodologically heterogeneous. There are no standardized protocols, and the effect of therapy on key clinical outcomes has not been sufficiently studied. It is necessary to systematize the available data in order to assess the current level of evidence and identify areas for further research. The aim of the study was to evaluate the effectiveness of PRP therapy in women with poor ovarian response and primary ovarian insufficiency. This systematic review included English-language publications evaluating the effectiveness of PRP therapy in women with diminished ovarian reserve and primary ovarian insufficiency for the period 1985–2025. The review is based on the PRISMA checklist. Randomized and non-randomized original clinical trials (prospective, retrospective, quasi-experimental, etc.) were used for the analysis. After searching for and excluding duplicates, 415 articles were screened, of which 4 studies were selected for qualitative synthesis. The included studies demonstrate that intraovarian PRP administration can help improve biomarkers of ovarian reserve (anti-Müllerian hormone, follicle-stimulating hormone, and antral follicle count), particularly in patients with poor ovarian response syndrome and after surgery. A positive trend in pregnancy and live birth rates was noted, with no increase in the rates observed. PRP therapy demonstrates potential effectiveness in improving ovarian reserve parameters. However, due to the small number of studies, their heterogeneity and varying risk of systematic error, the impact on final reproductive outcomes requires further research. Large, randomized, controlled trials are needed to standardize PRP preparation and administration protocols and define clear indications for therapy.